Celgene & Agios To Collaborate With Abbott To Identify IDH Mutations In AML

(RTTNews) - Celgene Corp. (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced each company has entered into collaboration agreements with Abbott (ABT) to develop and commercialize companion diagnostic tests on Abbott's m2000 RealTime System to identify isocitrate dehydrogenase, or IDH, mutations in acute myeloid leukemia, or AML, patients.

Celgene is currently developing enasidenib, an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Agios is developing AG-120, an IDH1 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation.

Abbott's m2000rt RealTime System is a polymerase chain reaction, or PCR, instrument designed to enable clinical laboratories to automate PCR and results analysis, simplifying the complex and manual steps often associated with molecular diagnostics.